[
  {
    "ts": null,
    "headline": "Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition",
    "summary": "JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.",
    "url": "https://finnhub.io/api/news?id=a13569c00eb6f477dbd725714e3b1f3400e945fb775f145586cda400ab76f34c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741173872,
      "headline": "Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition",
      "id": 133015816,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2180762109/image_2180762109.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.",
      "url": "https://finnhub.io/api/news?id=a13569c00eb6f477dbd725714e3b1f3400e945fb775f145586cda400ab76f34c"
    }
  }
]